FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286715926> ?p ?o ?g. }

• W4286715926 abstract "Abstract Background Bullous systemic lupus erythematosus (BSLE) is a rare subtype of systemic lupus erythematosus (SLE) that is clinically characterized by subepidermal tense vesicles or bullae. We aimed to investigate the clinical and laboratory features of patients with BSLE. Methods We retrospectively reviewed all patients who fulfilled the diagnostic criteria for BSLE in our institution from 2015 to 2021. Cutaneous lesions, systemic manifestations, treatment options, and outcomes were evaluated. For each case of BSLE, four controls were randomly selected from patients with single SLE. Major clinical and laboratory characteristics were compared between the two groups. Results Among 4221 patients with SLE, 12 developed BSLE. Vesiculobullous lesions were the first sign in five of the BSLE patients (5/12, 41.7%) and appeared after SLE diagnosis in the remaining seven patients (7/12, 58.3%), with a median duration from SLE onset of 36 months (4–115 months). The most common BSLE-affected sites were the head and neck (10/12, 83.3%), extremities (9/12, 75.0%), trunk (7/12, 58.3%), and mucosae (6/12, 50.0%). All patients with BSLE had extra-cutaneous involvement. The SLE disease activity index score exceeded 5 in 10/12 (83.3%) patients, which indicated high disease activity. Patients in the BSLE group had significantly higher incidences of proteinuria (83.3% vs. 47.9%, P = 0.027), hematuria (75% vs. 31.3%, P = 0.006), hemolytic anemia (33.3% vs. 0%, P = 0.000), and leukopenia (66.7% vs. 25.0%, P = 0.006) than those in the control group. The use of systemic corticosteroids, immunosuppressants, dapsone, and skin care was effective in controlling disease. Conclusions Vesiculobullous lesions may be the first manifestation and indicate a high disease activity in patients with BSLE. Early diagnosis using clinical, histopathological, and immunological evaluations can lead to appropriate treatment of this progressive disease and improve prognosis." @default.
• W4286715926 created "2022-07-23" @default.
• W4286715926 creator A5003463204 @default.
• W4286715926 creator A5008382096 @default.
• W4286715926 creator A5012278873 @default.
• W4286715926 creator A5024232551 @default.
• W4286715926 creator A5027475930 @default.
• W4286715926 creator A5057809167 @default.
• W4286715926 creator A5059300419 @default.
• W4286715926 creator A5073523669 @default.
• W4286715926 creator A5090435133 @default.
• W4286715926 date "2022-07-23" @default.
• W4286715926 modified "2023-09-28" @default.
• W4286715926 title "Clusters of clinical and immunologic features in patients with bullous systemic lupus erythematosus: experience from a single-center cohort study in China" @default.
• W4286715926 cites W1598610184 @default.
• W4286715926 cites W1925233986 @default.
• W4286715926 cites W1968993754 @default.
• W4286715926 cites W2011784300 @default.
• W4286715926 cites W2036170885 @default.
• W4286715926 cites W2042173676 @default.
• W4286715926 cites W2072498840 @default.
• W4286715926 cites W2098285534 @default.
• W4286715926 cites W2136265751 @default.
• W4286715926 cites W2159860161 @default.
• W4286715926 cites W2165576720 @default.
• W4286715926 cites W2327513924 @default.
• W4286715926 cites W2591124923 @default.
• W4286715926 cites W2602281737 @default.
• W4286715926 cites W2766717190 @default.
• W4286715926 cites W2804672569 @default.
• W4286715926 cites W2915912367 @default.
• W4286715926 cites W2957213808 @default.
• W4286715926 cites W2966041078 @default.
• W4286715926 cites W2995560263 @default.
• W4286715926 cites W3106621967 @default.
• W4286715926 doi "https://doi.org/10.1186/s13023-022-02445-z" @default.
• W4286715926 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35871005" @default.
• W4286715926 hasPublicationYear "2022" @default.
• W4286715926 type Work @default.
• W4286715926 citedByCount "2" @default.
• W4286715926 countsByYear W42867159262023 @default.
• W4286715926 crossrefType "journal-article" @default.
• W4286715926 hasAuthorship W4286715926A5003463204 @default.
• W4286715926 hasAuthorship W4286715926A5008382096 @default.
• W4286715926 hasAuthorship W4286715926A5012278873 @default.
• W4286715926 hasAuthorship W4286715926A5024232551 @default.
• W4286715926 hasAuthorship W4286715926A5027475930 @default.
• W4286715926 hasAuthorship W4286715926A5057809167 @default.
• W4286715926 hasAuthorship W4286715926A5059300419 @default.
• W4286715926 hasAuthorship W4286715926A5073523669 @default.
• W4286715926 hasAuthorship W4286715926A5090435133 @default.
• W4286715926 hasBestOaLocation W42867159261 @default.
• W4286715926 hasConcept C126322002 @default.
• W4286715926 hasConcept C159654299 @default.
• W4286715926 hasConcept C16005928 @default.
• W4286715926 hasConcept C198451711 @default.
• W4286715926 hasConcept C203014093 @default.
• W4286715926 hasConcept C2775915377 @default.
• W4286715926 hasConcept C2776694085 @default.
• W4286715926 hasConcept C2778248108 @default.
• W4286715926 hasConcept C2778674544 @default.
• W4286715926 hasConcept C2779134260 @default.
• W4286715926 hasConcept C2779561371 @default.
• W4286715926 hasConcept C2780073493 @default.
• W4286715926 hasConcept C2780091579 @default.
• W4286715926 hasConcept C2780873365 @default.
• W4286715926 hasConcept C71924100 @default.
• W4286715926 hasConcept C72563966 @default.
• W4286715926 hasConcept C90924648 @default.
• W4286715926 hasConceptScore W4286715926C126322002 @default.
• W4286715926 hasConceptScore W4286715926C159654299 @default.
• W4286715926 hasConceptScore W4286715926C16005928 @default.
• W4286715926 hasConceptScore W4286715926C198451711 @default.
• W4286715926 hasConceptScore W4286715926C203014093 @default.
• W4286715926 hasConceptScore W4286715926C2775915377 @default.
• W4286715926 hasConceptScore W4286715926C2776694085 @default.
• W4286715926 hasConceptScore W4286715926C2778248108 @default.
• W4286715926 hasConceptScore W4286715926C2778674544 @default.
• W4286715926 hasConceptScore W4286715926C2779134260 @default.
• W4286715926 hasConceptScore W4286715926C2779561371 @default.
• W4286715926 hasConceptScore W4286715926C2780073493 @default.
• W4286715926 hasConceptScore W4286715926C2780091579 @default.
• W4286715926 hasConceptScore W4286715926C2780873365 @default.
• W4286715926 hasConceptScore W4286715926C71924100 @default.
• W4286715926 hasConceptScore W4286715926C72563966 @default.
• W4286715926 hasConceptScore W4286715926C90924648 @default.
• W4286715926 hasIssue "1" @default.
• W4286715926 hasLocation W42867159261 @default.
• W4286715926 hasLocation W42867159262 @default.
• W4286715926 hasLocation W42867159263 @default.
• W4286715926 hasOpenAccess W4286715926 @default.
• W4286715926 hasPrimaryLocation W42867159261 @default.
• W4286715926 hasRelatedWork W1499054070 @default.
• W4286715926 hasRelatedWork W1974871686 @default.
• W4286715926 hasRelatedWork W2010633397 @default.
• W4286715926 hasRelatedWork W2011903210 @default.
• W4286715926 hasRelatedWork W2027246618 @default.
• W4286715926 hasRelatedWork W2141975906 @default.
• W4286715926 hasRelatedWork W2143913268 @default.
• W4286715926 hasRelatedWork W2385816051 @default.

• next